EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide.
(2015) In RMD Open 1(1). p.000022-000022- Abstract
- The EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) is a systemic disease activity index that was designed to measure disease activity in patients with primary SS. With the growing use of the ESSDAI, some domains appear to be more challenging to rate than others. The ESSDAI is now in use as a gold standard to measure disease activity in clinical studies, and as an outcome measure, even a primary outcome measure, in current randomised clinical trials. Therefore, ensuring an accurate and reproducible rating of each domain, by providing a more detailed definition of each domain, has emerged as an urgent need. The purpose of the present article is to provide a user guide for the ESSDAI. This guide provides definitions and... (More)
- The EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) is a systemic disease activity index that was designed to measure disease activity in patients with primary SS. With the growing use of the ESSDAI, some domains appear to be more challenging to rate than others. The ESSDAI is now in use as a gold standard to measure disease activity in clinical studies, and as an outcome measure, even a primary outcome measure, in current randomised clinical trials. Therefore, ensuring an accurate and reproducible rating of each domain, by providing a more detailed definition of each domain, has emerged as an urgent need. The purpose of the present article is to provide a user guide for the ESSDAI. This guide provides definitions and precisions on the rating of each domain. It also includes some minor improvement of the score to integrate advance in knowledge of disease manifestations. This user guide may help clinicians to use the ESSDAI, and increase the reliability of rating and consequently of the ability to detect true changes over time. This better appraisal of ESSDAI items, along with the recent definition of disease activity levels and minimal clinically important change, will improve the assessment of patients with primary SS and facilitate the demonstration of effectiveness of treatment for patients with primary SS. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8148095
- author
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- RMD Open
- volume
- 1
- issue
- 1
- pages
- 000022 - 000022
- publisher
- BMJ Publishing Group
- external identifiers
-
- pmid:26509054
- pmid:26509054
- scopus:85018192727
- ISSN
- 2056-5933
- DOI
- 10.1136/rmdopen-2014-000022
- language
- English
- LU publication?
- yes
- id
- 27d59ccf-0244-4eab-8988-df14fbd4bc3a (old id 8148095)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26509054?dopt=Abstract
- date added to LUP
- 2016-04-01 13:36:55
- date last changed
- 2022-04-21 22:37:00
@article{27d59ccf-0244-4eab-8988-df14fbd4bc3a,
abstract = {{The EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) is a systemic disease activity index that was designed to measure disease activity in patients with primary SS. With the growing use of the ESSDAI, some domains appear to be more challenging to rate than others. The ESSDAI is now in use as a gold standard to measure disease activity in clinical studies, and as an outcome measure, even a primary outcome measure, in current randomised clinical trials. Therefore, ensuring an accurate and reproducible rating of each domain, by providing a more detailed definition of each domain, has emerged as an urgent need. The purpose of the present article is to provide a user guide for the ESSDAI. This guide provides definitions and precisions on the rating of each domain. It also includes some minor improvement of the score to integrate advance in knowledge of disease manifestations. This user guide may help clinicians to use the ESSDAI, and increase the reliability of rating and consequently of the ability to detect true changes over time. This better appraisal of ESSDAI items, along with the recent definition of disease activity levels and minimal clinically important change, will improve the assessment of patients with primary SS and facilitate the demonstration of effectiveness of treatment for patients with primary SS.}},
author = {{Seror, Raphaèle and Bowman, Simon J and Brito-Zeron, Pilar and Theander, Elke and Bootsma, Hendrika and Tzioufas, Athanasios and Gottenberg, Jacques-Eric and Ramos-Casals, Manel and Dörner, Thomas and Ravaud, Philippe and Vitali, Claudio and Mariette, Xavier and Asmussen, Karsten and Jacobsen, Soren and Bartoloni, Elena and Gerli, Roberto and Bijlsma, Johannes Wj and Kruize, Aike A and Bombardieri, Stefano and Bookman, Arthur and Kallenberg, Cees and Meiners, Petra and Brun, Johan G and Jonsson, Roland and Caporali, Roberto and Carsons, Steven and De Vita, Salvatore and Del Papa, Nicoletta and Devauchelle, Valerie and Saraux, Alain and Fauchais, Anne-Laure and Sibilia, Jean and Hachulla, Eric and Illei, Gabor and Isenberg, David and Jones, Adrian and Manoussakis, Menelaos and Mandl, Thomas and Jacobsson, Lennart and Demoulins, Frederic and Montecucco, Carlomaurizio and Ng, Wan-Fai and Nishiyama, Sumusu and Omdal, Roald and Parke, Ann and Praprotnik, Sonja and Tomsic, Matjia and Price, Elizabeth and Scofield, Hal and L Sivils, Kathy and Smolen, Josef and Laqué, Roser Solans and Steinfeld, Serge and Sutcliffe, Nurhan and Sumida, Takayuki and Valesini, Guido and Valim, Valeria and Vivino, Frederick B and Vollenweider, Cristina}},
issn = {{2056-5933}},
language = {{eng}},
number = {{1}},
pages = {{000022--000022}},
publisher = {{BMJ Publishing Group}},
series = {{RMD Open}},
title = {{EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide.}},
url = {{https://lup.lub.lu.se/search/files/3478244/8839611.pdf}},
doi = {{10.1136/rmdopen-2014-000022}},
volume = {{1}},
year = {{2015}},
}